Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis.
anti-acetylcholine receptor antibody
antibody rebound
immunotherapy
myasthenia gravis
myasthenic crisis
plasmapheresis
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
27
05
2021
received:
30
11
2020
accepted:
28
05
2021
pubmed:
3
6
2021
medline:
29
9
2021
entrez:
2
6
2021
Statut:
ppublish
Résumé
Antibody overshoot following therapeutic plasmapheresis (PLEX) is defined by subsequent increase in antibody to levels exceeding those prior to removal. It has been infrequently described in the past, and its influence on the clinical course of myasthenia gravis (MG) remains unclear. This was a retrospective analysis of five patients with generalized MG treated with PLEX. All five patients possessed antibodies against acetylcholine receptor (AChR-Ab). After undergoing 3 to 12 PLEX treatment sessions, AChR-Ab titer increased to a median of 1292% of the baseline level. The median interval from the last PLEX session to peak AChR-Ab detection was 6 wk. In four patients, AChR-Ab overshoot was associated with a clinical deterioration. The AChR-Ab overshoot may occur following PLEX. In patients who deteriorate following PLEX treatment, the presence of antibody overshoot may serve as additional guidance for treatment adjustment.
Substances chimiques
Anti-Inflammatory Agents
0
Autoantibodies
0
Receptors, Cholinergic
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
483-487Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002;(4):CD002275.
Guptill JT, Juel VC, Massey JM, et al. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity. 2016;49(7):472-479.
Yeh J-H, Chen W-H, Chiu H-C, Bai C-H. MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis. J Neurol Sci. 2007;263(1-2):191-193.
Derksen RH, Schuurman HJ, Gmelig Meyling FH, Struyvenberg A, Kater L. Rebound and overshoot after plasma exchange in humans. J Lab Clin Med. 1984;104(1):35-43.
Nasca TJ, Muder RR, Thomas DB, Schrecker JC, Ruben FL. Antibody response to pneumococcal polysaccharide vaccine in myasthenia gravis: effect of therapeutic plasmapheresis. J Clin Apher. 1990;5(3):133-139.
Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of america. Ann Thorac Surg. 2000;70(1):327-334.
Yamada C, Ramon DS, Cascalho M, et al. Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients. Transfusion. 2015;55:727-735.
Blume OR, Yost SE, Kaplan B. Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes. J Transplant. 2012;2012:201754.
Dau PC. Increased antibody production in peripheral blood mononuclear cells after plasma exchange therapy in multiple sclerosis. J Neuroimmunol. 2000;62(2):197-200.
Dau PC, Lindstrom JM, Cassel CK, et al. Plasmapheresis in myasthenia gravis and polymyositis. In: Dau PC, ed. Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston, MA: Houghton Mifflin Co; 1979:229-247.
Keesey J. Indications for thymectomy in myasthenia gravis. In: Dau PC, ed. Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston, MA: Houghton Mifflin Co; 1979:124-136.
Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (regain): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976-986.
Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord. 2011;4(5):259-266.
Sanders DB, Burns TM, Cutter GR, et al. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve. 2014;49(4):483-486.
Arsura EL, Bick A, Brunner NG, Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci. 1988;295(5):438-443.
Hellmann MA, Mosberg-Galili R, Lotan I, Steiner I. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity. J Neurol Sci. 2014;338(1-2):39-42.
Dau PC. Immunologic rebound. J Clin Apher. 1995;10(4):210-217.